Anaemia is a common complication of myelofibrosis, a rare chronic condition affecting blood cell production. The condition is driven by mutations in genes like JAK2, CALR, and MPL, causing abnormal cellular proliferation and disrupted haematopoiesis. Anaemia in myelofibrosis is challenging to manage, typically requiring transfusions and limited treatment options like erythropoiesis-stimulating agents (ESAs) or androgens. Newer therapies like JAK inhibitors and luspatercept show promise in improving anaemia but have limitations. Stem cell transplantation is the only curative option but comes with risks. A multidisciplinary approach involving various specialists is crucial for optimal anaemia management in myelofibrosis.
Source link
Myelofibrosis and moderate to severe anaemia
